Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aspacytarabine - Ayala Pharmaceuticals

Next Previous
Drug Profile

Aspacytarabine - Ayala Pharmaceuticals

Alternative Names: Ara-C asparagine conjugate; Aspacytarabine-hydrochloride-Ayala Pharmaceuticals; Asparagine ara-C conjugate; Asparagine cytarabine conjugate; Astarabine; BSR-236; BST 236; BST-236-HCl; Cytarabine asparagine conjugate; Cytarabine-prodrug

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioSight
  • Developer Ayala Pharmaceuticals; Groupe Francophone des Myelodysplasies
  • Class Amino acids; Antineoplastics; Arabinonucleosides; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 13 Jan 2025 Groupe Francophone des Myelodysplasies completes a Phase-II clinical trials in Myelodysplastic syndromes and Acute myeloid leukemia (Monotherapy, Second-line therapy or greater) in France (IV) (EudraCT2020-003400-13) (NCT04827719)
  • 04 Apr 2024 Ayala Pharmaceuticals files for patent protection for Aspacytarabine in Australia, Brazil, Canada, China, Europe, India, Japan, Israel, Russia, Korea, Hong Kong and the United States
  • 04 Apr 2024 Ayala Pharmaceuticals has patent protection for BST 236 composition and use in United States, Europe, Australia, Israel, Canada, Japan, Russia, India, Macau, China and Monaco

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top